100757-91-3

Upstream product

• 201230-82-2 carbon monoxide 
• 619-44-3 methyl 4-iodobenzoate 
• 100-99-2 triisobutylaluminum 
• 926-62-5 isobutylmagnesium bromide 
• 1571-08-0 methyl 4-formylbenzoate 
• 5674-02-2 2-methylpropylmagnesium chloride 
• 590-86-3 isovaleraldehyde 
• 619-58-9 4-iodobenzoic acid 
• 186581-53-3 diazomethane 

Downstream Products

• 121198-78-5 1-(4-methoxycarbonylphenyl)-3-methyl-1-butanone 
• 954148-11-9 3-{4-[1-(4'-tert-butyl-biphenyl-4-ylmethyl)-3-methyl-butyl]-benzoylamino}-propionic acid, Isomer 1 
• 954148-08-4 3-{4-[1-(4'-tert-butyl-biphenyl-4-ylmethyl)-3-methyl-butyl]-benzoylamino}-propionic acid, Isomer 2 
• 954148-10-8 3-{4-[1-(4'-tert-butyl-biphenyl-4-ylmethyl)-3-methyl-butyl]-benzoylamino}-propionic acid methyl ester, Isomer 1 
• 954148-09-5 3-{4-[1-(4'-tert-butyl-biphenyl-4-ylmethyl)-3-methyl-butyl]-benzoylamino}-propionic acid methyl ester, Isomer 2 
• 954147-94-5 3-{4-[1-(4'-tert-butyl-biphenyl-4-ylmethyl)-3-methyl-butyl]-benzoylamino}-propionic acid 
• 954147-97-8 3-{4-[1-(4'-tert-butyl-biphenyl-4-ylmethyl)-3-methyl-butyl]-benzoylamino}-propionic acid methyl ester 
• 872255-22-6 3-{4-[3-methyl-1-(4'-trifluoromethoxy-biphenyl-4-ylsulfanyl)-butyl]-benzoylamino}-propionic acid methyl ester 
• 872255-21-5 3-{4-[1-(4-bromo-phenylsulfanyl)-3-methyl-butyl]-benzoylamino}-propionic acid methyl ester 
• 872255-20-4 4-[1-(4-bromo-phenylsulfanyl)-3-methyl-butyl]-benzoic acid 
• 953798-84-0 4-[1-(4-bromo-3,5-dimethyl-phenoxy)-2-methyl-propyl]-benzoic acid methyl ester 

Relevant academic research and scientific papers

Discovery of potent and orally bioavailable indazole-based glucagon receptor antagonists for the treatment of type 2 diabetes

Type 2 diabetes mellitus (T2DM) is characterized by chronically elevated plasma glucose levels. The inhibition of glucagon-induced hepatic glucose output via antagonism of the glucagon receptor (GCGR) using a small-molecule antagonist is a promising mecha

INDAZOLE DERIVATIVES USEFUL AS GLUCAGON RECEPTOR ANTAGONISTS

The present invention is directed to indazole derivatives, pharmaceutical compositions containing them and their use in the treatment and/or prevention of disorders and conditions ameliorated by antagonizing one or more glucagon receptors, including for e

INDAZOLE DERIVATIVES USEFUL AS GLUCAGON RECEPTOR ANTAGONISTS

The present invention is directed to indazole derivatives, pharmaceutical compositions containing them and their use in the treatment and/or prevention of disorders and conditions ameliorated by antagonizing one or more glucagon receptors, including for e

INDOLE DERIVATIVES USEFUL AS GLUCAGON RECEPTOR ANTAGONISTS

The present invention is directed to indole derivatives, pharmaceutical compositions containing them and their use in the treatment and/or prevention of disorders and conditions ameliorated by antagonizing one or more glucagon receptors, including for example metabolic diseases such as Type II diabetes mellitus and obesity.

GLUCAGON RECEPTOR MODULATORS

The present invention provides a compound of Formula (I) or a pharmaceutically acceptable salt thereof wherein R1, R2, R3, A1, A2, A3, A4, L, B1, B2, B3 and B4 are as defined herein. The compounds of Formula I have been found to act as glucagon antagonists or inverse agonists. Consequently, the compounds of Formula I and the pharmaceutical compositions thereof are useful for the treatment of diseases, disorders, or conditions mediated by glucagon.

GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES

The present invention discloses novel compounds of Formula (I), or pharmaceutically acceptable salts thereof, which have glucagon receptor antagonist or inverse agonist activity, as well as methods for preparing such compounds. In another embodiment, the

Activation of functional arylzincs prepared from aryl iodides and highly enantioselective addition to aldehydes

(Chemical Equation Presented) An easily available chiral ligand (S)-1 is found to activate the nucleophilic reaction of the arylzincs prepared in situ from the reaction of aryl iodides with Et2Zn. Both high yields and high enantioselectivity (u

Glucagon Receptor Antagonists, Preparation and Therapeutic Uses

The present invention discloses novel compounds of Formula I, or pharmaceutically acceptable salts thereof, which have glucagon receptor antagonist or inverse agonist activity, as well as methods for preparing such compounds. In another embodiment, the in

GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES

The present invention discloses novel compounds of Formula I, or pharmaceutically acceptable salts thereof, which have glucagon receptor antagonist or inverse agonist activity, as well as methods for preparing such compounds. In another embodiment, the in

GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES

The present invention discloses novel compounds of Formula I, or pharmaceutically acceptable salts thereof, which have glucagon receptor antagonist or inverse agonist activity, as well as methods for preparing such compounds. In another embodiment, the in